Pharmaceutical Product Development, LLC (PPD) has created a dedicated unit combining its medical affairs research operations (MARO) team and Evidera, a provider of evidence-based solutions to demonstrate the real-world effectiveness, safety and value of biopharmaceuticals. PPD acquired Evidera last year.
 
The new unit, retaining the Evidera name, will provide solutions, including modeling and simulation, interventional studies (including expanded access/compassionate use and extended access), observational studies (including registries), health economics, outcomes research, market access, epidemiology, real-world evidence, safety and risk management.
 
“Our clients are seeking better evidence to satisfy the requirements of both regulators and payers, and we have a tremendous opportunity to meet that need by delivering real-world evidence that bridges the gaps between efficacy, safety and value,” said William Sharbaugh, chief operating officer of PPD. “Through this new business unit we will be able to help our clients seamlessly integrate and align regulatory and peri- and post-approval research efforts, improving their ability to meet the evidence demands of both regulators and payers.”
 
The new business unit will retain the executive and scientific leadership of both the Evidera and MARO organizations. Jon Williams, who has served as president and chief executive officer of Evidera since 2013, will lead the new unit.
 
“Bringing together Evidera’s scientific and consulting expertise with PPD’s global operations infrastructure creates an unparalleled ability to partner with and serve our clients in optimizing their product value and market access,” Mr. Williams said.